Inclisiran reduces LDL cholesterol by up to 54.7% in patients with atherosclerotic cardiovascular diseaseTrial shows consistent cholesterol reduction for heart disease patients

This Phase 3 randomized controlled trial, presented as a post hoc pooled analysis, evaluated the efficacy and safety of inclisiran in a large cohort of 3,660 patients. The study population specifically included individuals with heterozygous familial hypercholesterolemia (HeFH), atherosclerotic cardiovascular disease (ASCVD) or its risk equivalent, and elevated LDL cholesterol levels. The primary objective was to assess the percentage change in LDL cholesterol at day 510 and the time-adjusted percentage change from day 90 through day 540.

The intervention consisted of inclisiran administered via subcutaneous injection on days 1 and 90, followed by injections every 6 months for a total duration of 540 days. The treatment was compared against a placebo group. This dosing regimen is designed to provide sustained lipid lowering with infrequent administration.

Primary outcome results demonstrated significant reductions in LDL cholesterol at day 510 across all renal function categories. For patients with eGFR ≥90, there was a -49.9% reduction (n=1610; -53.2 to -46.6; P < 0.001). Patients with eGFR between 60 and <90 showed a -51.2% reduction (n=1608; -54.4 to -48.0; P < 0.001). In the eGFR 45 to <60 group, LDL cholesterol decreased by -54.7% (n=300; -62.5 to -47.0; P < 0.001). For those with impaired renal function (eGFR 15 to <45), a reduction of -44.7% was observed (n=142; -57.6 to -31.8; P < 0.001).

Time-adjusted results from day 90 through day 540 reinforced these findings. The percentage change in LDL cholesterol was -48.4% for eGFR ≥90, -51.8% for eGFR 60 to <90, -55.6% for eGFR 45 to <60, and -50.4% for eGFR 15 to <45 (all P < 0.001). These data indicate that the magnitude of LDL reduction remains robust even in patients with significant renal impairment.

Secondary outcomes included measurements of total cholesterol, apolipoprotein B, non-HDL cholesterol, and lipoprotein(a). While specific numerical values for these secondary endpoints were not detailed in the primary results summary provided, they contribute to the overall lipid profile assessment. Safety and tolerability findings indicated that inclisiran was well tolerated without new safety findings reported during the study period.

These results align with the clinical need for effective therapies in patients with HeFH and ASCVD. The data specifically confirm that inclisiran maintains efficacy regardless of baseline eGFR as low as 15 ml/min per 1.73 m2, which is a critical consideration for managing patients with comorbid chronic kidney disease. Methodological limitations include the fact that this is a post hoc pooled analysis of three Phase 3 trials, which may introduce certain biases inherent to retrospective data grouping. However, the large sample size (n=3660) and clear p-values (< 0.001) across all subgroups provide high confidence in the primary findings. Clinical implications suggest that inclisiran can be a reliable option for LDL reduction in diverse patient populations with varying renal functions.

Questions remain regarding long-term durability beyond 540 days and the specific impact on hard cardiovascular endpoints compared to standard of care in this specific population. However, the consistent reduction across eGFR strata provides strong evidence for its use in complex lipid management cases.